To compare clinical and cost-effectiveness of treating recurrent preterm labor (RPTL) with oral nifedipine versus continuous subcutaneous terbutaline infusion (SQT).
INTRODUCTION
The principal pathways leading to preterm delivery are generally believed to be spontaneous preterm labor, preterm premature rupture of the membranes (pPROM), or medically indicated induction. 1 Of these pathways, preterm labor often provides the clinician the greatest opportunity for interventions that may prolong pregnancy.
Preterm labor is thought to be multifactorial in etiology. In most cases when a woman presents with uterine activity and subjective symptoms of preterm labor, the cause is not immediately apparent and many times remains unknown. This creates a challenge for the physician in the selection of appropriate intervention(s) and treatment(s). Inhibition of uterine contractions with pharmacologic agents (tocolysis) is the mainstay of treatment for acute preterm labor. Numerous studies have demonstrated that, in the majority of patients, an acute event of preterm labor can be successfully treated with magnesium sulfate, beta-adrenergic agents such as terbutaline, or nifedipine. 2, 3 After an arrest of an acute episode of preterm labor, a treatment plan is often developed that provides for close patient observation. Ongoing tocolysis is frequently prescribed in an effort to maintain uterine quiescence, control preterm labor symptoms, prevent recurrent preterm labor, and prolong gestation. Nonetheless, even patients stabilized and transitioned to ongoing maintenance tocolysis frequently experience recurrent preterm labor that results in hospitalization, retreatment with parenteral tocolytics, or preterm delivery. A single episode of preterm labor is a significant risk factor for preterm birth. Even following successful treatment of acute preterm labor, approximately 50% of women will still deliver prematurely, despite ongoing tocolytic therapy. [4] [5] [6] Early recognition of the symptoms of recurrent preterm labor is most advantageous for treatment success. To address the need for close observation and early recognition, outpatient programs are available that provide nursing services, home uterine contraction monitoring, telephonic nursing availability 24 hours/day and 7 days/week for patient assessment and intervention, and assistance in coordination of required social services.
Preterm birth is the single most important cause of perinatal mortality in much of the world and is a major determinant of neonatal and infant morbidity, as well as a considerable economic burden. An estimated $10.2 billion is spent annually for newborn medical care in the United States. 7 Although approximately 12% of all pregnancies in the United States end with preterm delivery, billion of total dollars, spent on initial neonatal care. 7 Of all hospital admissions, four of the ten most expensive diagnoses are related to the care of neonates with complications following delivery (respiratory distress, prematurity, cardiac anomaly, lack of oxygen/asphyxia). (http://www.ahrq.gov/data/hcup/hcupnet.htm.) 9 Consequently, there are both societal and financial incentives for prolonging gestation in women presenting with preterm labor.
The purpose of the present analysis was to compare gestational days gained and the associated costs of using oral nifedipine versus continuous subcutaneous terbutaline infusion for ongoing tocolysis in patients with recurrent preterm labor.
STUDY DESIGN
The patient population for this retrospective study was extracted from an electronic database (Matria Healthcare, Marietta, GA). This database is comprised of clinical data prospectively collected from women enrolled by their health-care provider in outpatient programs related to a high-risk pregnancy condition. Upon initiation of outpatient services, all women give signed, informed consent agreeing to the use of blinded data for research purposes.
From data collected between June 1992 and June 2000, we identified women meeting the following criteria: (1) singleton gestation, (2) prescribed nifedipine following an initial episode of preterm labor, (3) subsequent hospitalization for recurrent preterm labor at <34 weeks, (4) stabilized by tocolysis per attending physician's plan of treatment, and (5) outpatient tocolysis resumed with nifedipine or continuous subcutaneous terbutaline. Criteria used to make the diagnosis and in-patient treatment of preterm labor were not documented in the electronic outpatient record and thus were unable to be reported in this study.
Data were divided into two treatment groups: women prescribed oral nifedipine (NIF group) and those prescribed continuous subcutaneous terbutaline (SQT group). By gestational age (GA) at the episode of recurrent preterm labor, each patient in the NIF group was matched in random fashion 1:1 to a patient in the SQT group. Patients without a match were not included in the analysis. Matching was conducted in order to control for differences in GA at study entry, thus allowing for a better comparison of treatment efficacy.
Women in both groups received on-going prenatal care from their individual health-care provider. In addition, all participants continued to receive outpatient preterm labor management services. This outpatient program consisted of an individual patient-teaching session with a registered nurse regarding the signs and symptoms of preterm labor and use of a monitoring device for electronic collection of uterine contraction data in the patient's home. Those in the SQT group received additional education sessions relating to subcutaneous infusion pump use and initiation and care of the subcutaneous infusion site. Following the initial home visit, follow-up visits were conducted on an as-needed basis. Specially trained perinatal nurses were available 24 hours/day and 7 days/week for data evaluation, patient calls, and nursing support. Uterine contraction data were collected at a minimum of 1 hour twice daily, 8 to 10 hours apart, and as needed based on monitoring results or an increase in preterm labor signs and symptoms. Data were transmitted to a perinatal center staffed with registered nurses who evaluated the data received and completed a telephonic assessment of signs and symptoms of preterm labor. Adherence to the prescribed medication regimen and other physician orders was also encouraged, assessed and documented daily. The physician was contacted for additional orders when uterine activity exceeded an established threshold (generally 4 to 6 contractions per hour). Interventions such as medication dosing, hospital admission, and changes in recommended patient activity level were at the discretion of each patient's attending physician.
Continuous subcutaneous terbutaline was administered via a portable microinfusion pump (Minimed s Technologies, Sylmar, CA, or Disetronics, Minneapolis, MN). The infusion device was programmed to deliver a continuous basal rate and intermittent bolus doses. Each patient's physician-prescribed dosage schedule was based on her uterine activity pattern, subjective symptoms, and body mass index.
To evaluate the cost-effectiveness of each treatment, a model was applied where charges incurred during the study period for antepartum hospitalization, outpatient services, and nursery days were standardized. In this model, maternal antepartum hospital days were estimated at $1940/day, normal newborn nursery at $620/day, NICU with low birth weight at $2508/day, and NICU with other perinatal conditions at $2817/day. These numbers were obtained from the Agency for Healthcare Research and Quality, Nationwide Inpatient Sample for 1999. 9 Outpatient nursing services with continuous subcutaneous terbutaline were calculated at $250/ day and outpatient nursing services with nifedipine at $70/day. The estimated cost per day for hospital care combines accommodation and ancillary charges and does not take into account indirect costs.
Primary study outcomes were days gained following recurrent preterm labor, delivery <35 weeks, and estimated maternal antepartum/newborn costs during the study period. Parametric data were analyzed using Student's paired t, and nonparametric data were analyzed using Wilcoxon Signed Rank and McNemar's w 2 . Statistical significance was concluded for two-sided p-values <0.05.
RESULTS
Data from a total of 284 women, or 142 matched pairs, were analyzed. Maternal characteristics are summarized in Table 1 . Overall, patients experienced their first episode of preterm labor and initiation of oral nifedipine at a mean GA of 27.8±3.2 weeks.
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The mean GA at recurrent preterm labor was 30.4±2.6 weeks (matched variable). In all, 66.2, 34.5, and 16.9% of matched pairs were <32, <30, and <28 weeks, respectively, at the time of recurrent preterm labor. There was no difference in GA at first preterm labor for those resuming nifedipine following recurrent preterm labor (27.9±3.1 weeks at first preterm labor) and for those ultimately receiving continuous subcutaneous terbutaline following recurrent preterm labor (27.6±3.3 at first preterm labor), p ¼ 0.256. Nifedipine and terbutaline dosing was per each patient's attending physician. Women in the NIF group received a mean of 66.7±37.1 mg of nifedipine daily. Those in the SQT group received a mean of 3.2±1.6 mg of terbutaline daily, administered subcutaneously via a microinfusion pump. Gestational gain following recurrent preterm labor is summarized in Table 2 . Women in the SQT group had greater gestational gain. Both groups had a similar incidence of pregnancy prolongation >7 days, but those in the SQT group were more likely to have pregnancy prolonged more than 2 weeks versus women in the NIF group. In total, 84% of days gained by SQT patients and 73.0% of days gained by NIF patients were outpatient days, pr0.001. The mean total pregnancy prolongation from the first episode of preterm labor to delivery for these particularly high-risk women experiencing recurrent preterm labor was 54.2±27.9 days for the NIF group and 62.7±26.8 days for the SQT group, p ¼ 0.002. Overall, from the first preterm labor episode, women transitioned to SQT following recurrent preterm labor gained a mean of 8.5 more days than women resuming nifedipine.
Pregnancy outcome is summarized in Table 3 . Those receiving SQT had a later mean GA at delivery and a lower incidence of delivery at <35.0 and <32.0 weeks than women in the NIF group. In all, 30 women (21.2%) in the NIF group versus 14 (9.9%) in the SQT group delivered at <35.0 weeks due to preterm labor, p ¼ 0.001. There were three stillborn infants, one at 29 weeks (NIF group), one at 35 weeks (SQT group), and one at 40 weeks (SQT group). Two stillbirths were unexplained, and one was attributed to a cord accident. Women in the NIF group were almost twice as likely to have their infant admitted to the neonatal intensive care unit (NICU), resulting in nursery costs almost three times that of an infant from the SQT group. A comparison of estimated costs related to antepartum hospitalization, outpatient services, and nursery charges is presented in Table 4 . Estimated charges for antepartum hospitalization and outpatient services following recurrent preterm labor, as well as infant nursery care, totaled $5,259,640 for the NIF group versus $3,769,606 for the SQT group. Approximately 40% of total charges ($2,114,890) for the NIF group versus 12% of total charges ($462,004) for the SQT group were a result of delivery at less than 32 weeks.
CONCLUSION
To our knowledge, this is the first analysis that compares the clinical and cost effectiveness of oral nifedipine versus continuous subcutaneous terbutaline for ongoing tocolytic therapy in women with recurrent preterm labor.
The choice of tocolytic agent is often a difficult decision. The risks and complications of tocolytic drugs are well documented. [10] [11] [12] No perfect tocolytic medication exists that is without potential problems for mother, fetus, or newborn. Physiologic, metabolic, and cardiopulmonary complications ranging from mild to severe have been associated with the use of beta-adrenergic medications such as terbutaline given by any route, 10 although the incidence of drug-related side effects may be lessened with continuous low-dose subcutaneous administration. 13 The incidence of cardiopulmonary complications in 8709 women receiving subcutaneous terbutaline infusion reported by Perry et al. 13 was 0.54%. Cardiopulmonary complications are dose-and route-dependent and more frequent when multiple agents are simultaneously utilized for tocolysis, in multiple gestations, or when infection or underlying heart disease is present. 10, 11 It has been suggested that nifedipine may have more utility as a tocolytic agent than terbutaline due to fewer maternal side effects and ease of oral administration, 14, 15 although nifedipine has been associated with maternal hypotension, 16 hemodilutional changes, 14 neuromuscular blockade, 17 and cardiac toxicity. 12 Nifedipine readily crosses the placenta. Long-term maternal and fetal effects, if any, are unknown. Studies of the effects of nifedipine in hypertensive patients have suggested a higher risk for cancer and perioperative bleeding. 12 Patients receiving any tocolytic medication should be monitored carefully for symptoms of developing complications and compliance with prescribed dosage, as were the patients in this study. Compliance with oral tocolytic regimens is less than optimal, and may influence efficacy. Indeed, in one study, only 50 to 65% of patients were compliant with taking at least 80% of their prescribed tocolytic dosage. 18 In 1988, in an effort to reduce problems with medication compliance and cardiopulmonary side effects, and possibly delay the onset of tachyphylaxis, Lam et al. 19 first described using a microinfusion pump to administer subcutaneously a low-dose, continuous basal rate and scheduled bolus doses of terbutaline. Since 1988, there have been many publications further describing the use of SQT in a variety of different patient populations. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] All patients in this current study were enrolled in a comprehensive outpatient preterm labor management program. The impact of this program, which included patient education, uterine activity monitoring, and both daily and as-needed nursing assessment, is unable to be evaluated within this study framework since all patients (both study groups) received outpatient services.
Previous studies of patients not enrolled in comprehensive outpatient preterm labor management programs that received ongoing tocolysis with nifedipine reported a mean gestational gain of 37, 6 28, 30 31, 31 and 39 days; 15 considerably less than the mean gain of 54.2 days gained with nifedipine in the present study. Investigations of patients receiving SQT without a comprehensive outpatient preterm labor management program reported a mean gestational gain of 29 days 27 and 35 days 25 following an initial episode of preterm labor. Women in the present study receiving comprehensive perinatal home care services and on-going tocolysis with nifedipine then SQT gained a mean total of 62.7 days following initial preterm labor (19.5 days with nifedipine and 43.3 days with SQT).
This analysis was not designed to determine the overall efficacy or safety of ongoing tocolysis following stabilization of an acute episode of preterm labor. While the debate over tocolytic efficacy persists, many physicians will continue to prescribe ongoing tocolysis for patients following an episode of preterm labor in an effort to maintain uterine quiescence and prolong gestation. Our goal was to compare overall time gained in utero following recurrent preterm labor and costs incurred with oral nifedipine therapy versus SQT. We found that women with singleton gestations experiencing recurrent preterm labor during oral nifedipine therapy achieved greater pregnancy prolongation with lower estimated maternal antepartum hospital/outpatient and newborn costs following an alteration of treatment to SQT than with reinitiation of oral nifedipine. The benefit of improved outcomes far outweighed the higher costs related to outpatient treatment with SQT. We acknowledge that the retrospective, nonrandomized design of this analysis, as well as the lack of a placebo control group, limits what may be concluded from our observations. However, it is also important to note that our focus was on treatments initiated after recurrence of preterm labor, and all women were hospitalized for acute treatment prior to the study period. These factors emphasize the acuity of the overall study population. Matching patients on GA at recurrence of preterm labor further controlled for differences in outcome not attributable to the treatments studied.
The cost data in this study were estimated. This was done due to the nationwide distribution of patients. A standardized model eliminates regional variations in charges, as well as equalizes the inflationary impact. In addition, we only analyzed charges occurring after recurrent preterm labor. Physician charges were not included in this analysis. In determining antepartum charges we did not include charges for hospital observation admissions of less than 24 hours, which may also decrease overall estimated charges for inpatient care. Outpatient nursing services were estimated at $250 per day for those receiving continuous subcutaneous terbutaline and $70 per day for those receiving oral terbutaline, although actual charges may have varied widely based on contractual arrangements. The outpatient service fee included Fleming et al. Economic Outcomes in RPTL patient education materials, home nursing visits, daily telephonic assessment, durable medical equipment (uterine monitor for both groups, and microinfusion pump and supplies for the subcutaneous terbutaline group), and cost of tocolytic medication. In this analysis, overall savings were realized through a reduction in NICU utilization and overall nursery days for infants of the subcutaneous terbutaline group. We believe that the greater prolongation of pregnancy and better neonatal outcomes in the SQT group were related to more precise tocolytic dosing afforded by the programmable, microinfusion pump, a reduced incidence of myometrial desensitization (tachyphylaxis), and improved patient tolerance and compliance with medication administration. We further hypothesize that patients receiving ongoing tocolysis who experience recurrent preterm labor may derive benefit through an alteration of tocolytic agent or medication delivery route and close outpatient surveillance as utilized in our investigation.
